Anti-PECAM therapy for metastasis suppression
The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases.
1. A method for repressing metastasis of a neoplastic cell, the method comprising administering a therapeutically effective amount of an anti-PECAM antibody via systemic administration to a mammal having one or more metastases.
2. The method of claim 1 , wherein the anti-PECAM antibody is a monoclonal antibody.
3. The method of claim 1 , wherein the neoplastic cell is a melanoma cell, a breast carcinoma cell, colon carcinoma cell, or a lung carcinoma cell.
4. The method of claim 1 , wherein the neoplastic cell is a human cell.
5. The method of claim 2 , wherein the monoclonal antibody is administered to the mammal via intraperitoneal injection.
6. The method of claim 2 , wherein the administration of monoclonal antibody is commenced after tumor growth has been established in said mammal.
7. The method of claim 6 , wherein the monoclonal antibody is administered after tumor cells have been present in the circulatory system of said mammal for at least 7 days prior to said administration of monoclonal antibody.
8. The method of claim 6 , wherein the neoplastic cells are human tumor cells.
9. The method of claim 1 , wherein the anti-PECAM antibody is administered to the mammal in a plurality of doses wherein each dose comprises at least 200 micrograms of anti-PECAM antibody and said plurality of doses comprise at least five doses with each dose administered at least two days apart.
10. The method of claim 9 , wherein the antibody is administered after tumor cells have been present in the circulatory system of said mammal for at least 7 days prior to said administration of antibody.
11. The method of claim 1 , wherein the antibody is administered to the mammal via intravenous injection.